RxDoctor Payments Data

Rashid Saba, DO

Internal Medicine · Land O Lakes, FLNPI 1376612481

Payments from drug & device makers

$396in general payments, 2019–2025

Across 17 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$119
  • Sunovion Pharmaceuticals Inc.$45
  • Novo Nordisk$39
  • Sun Pharmaceutical Industries Inc.$39
  • Collegium Pharmaceutical, Inc.$38
  • Pfizer$29
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$396 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$113,026
Medicare patients
300
Services billed
1,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate66$51,888
Ergotamine-CaffeineErgotamine Tartrate/Caffeine26$38,777
Oxycodone Hcl588$15,045
Naproxen39$9,184
EliquisApixaban15$9,068
LinzessLinaclotide16$8,465
Morphine Sulfate ErMorphine Sulfate250$7,872
Oxymorphone Hcl ErOxymorphone Hcl14$5,290
Ondansetron Hcl17$4,724
Cyclobenzaprine Hcl153$3,255
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen68$3,252
Hydromorphone Hcl66$3,165
Ibuprofen260$2,805
Lidocaine15$1,477
Naloxone Hcl14$1,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$38$51,88866 claims
PfizerEliquis$29$9,06815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Land O Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →